These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11973489)

  • 1. Reproducibility and clinical value of 18F-fluorodeoxyglucose positron emission tomography in recurrent melanoma.
    Mijnhout GS; Comans EF; Raijmakers P; Hoekstra OS; Teule GJ; Boers M; De Gast GC; Adèr HJ
    Nucl Med Commun; 2002 May; 23(5):475-81. PubMed ID: 11973489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET.
    Kalff V; Hicks RJ; Ware RE; Greer B; Binns DS; Hogg A
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):506-15. PubMed ID: 11914889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of the literature for whole-body FDG PET in the management of patients with melanoma.
    Schwimmer J; Essner R; Patel A; Jahan SA; Shepherd JE; Park K; Phelps ME; Czernin J; Gambhir SS
    Q J Nucl Med; 2000 Jun; 44(2):153-67. PubMed ID: 10967625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients.
    Rinne D; Baum RP; Hör G; Kaufmann R
    Cancer; 1998 May; 82(9):1664-71. PubMed ID: 9576286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and Prognostic Value of
    Albano D; Familiari D; Fornito MC; Scalisi S; Laudicella R; Galia M; Grassedonio E; Ruggeri A; Ganduscio G; Messina M; Spada M; Midiri M; Alongi P
    Curr Radiopharm; 2020; 13(1):42-47. PubMed ID: 31595860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer.
    De Potter T; Flamen P; Van Cutsem E; Penninckx F; Filez L; Bormans G; Maes A; Mortelmans L
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):525-9. PubMed ID: 11914891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact.
    Stas M; Stroobants S; Dupont P; Gysen M; Hoe LV; Garmyn M; Mortelmans L; Wever ID
    Melanoma Res; 2002 Oct; 12(5):479-90. PubMed ID: 12394190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
    Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
    Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
    Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for the Detection of Recurrent Disease after Treatment of Malignant Melanoma.
    Lee JW; Nam SB; Kim SJ
    Oncology; 2019; 97(5):286-293. PubMed ID: 31437839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma?
    Fuster D; Chiang S; Johnson G; Schuchter LM; Zhuang H; Alavi A
    J Nucl Med; 2004 Aug; 45(8):1323-7. PubMed ID: 15299056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making.
    Gulec SA; Faries MB; Lee CC; Kirgan D; Glass C; Morton DL; Essner R
    Clin Nucl Med; 2003 Dec; 28(12):961-5. PubMed ID: 14663316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical impact of 18F-FDG gamma PET in patients with recurrent well differentiated thyroid carcinoma.
    Goshen E; Cohen O; Rotenberg G; Oksman Y; Karasik A; Zwas ST
    Nucl Med Commun; 2003 Sep; 24(9):959-61. PubMed ID: 12960594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging methods.
    Krug B; Dietlein M; Groth W; Stützer H; Psaras T; Gossmann A; Scheidhauer K; Schicha H; Lackner K
    Acta Radiol; 2000 Sep; 41(5):446-52. PubMed ID: 11016764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG PET/CT and Melanoma: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management.
    Mena E; Taghipour M; Sheikhbahaei S; Mirpour S; Xiao J; Subramaniam RM
    Clin Nucl Med; 2016 Sep; 41(9):e403-9. PubMed ID: 27355846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of whole body 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer.
    Sun SS; Chen TC; Yen RF; Shen YY; Changlai SP; Kao A
    Anticancer Res; 2001; 21(4B):2957-61. PubMed ID: 11712793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of metastases in patients with cutaneous melanoma using FDG-PET/CT.
    Akcali C; Zincirkeser S; Erbagcý Z; Akcali A; Halac M; Durak G; Sager S; Sahin E
    J Int Med Res; 2007; 35(4):547-53. PubMed ID: 17697533
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Jaeger ZJ; Williams GA; Chen L; Mhlanga JC; Cornelius LA; Fields RC
    J Surg Oncol; 2022 Mar; 125(3):525-534. PubMed ID: 34741547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
    Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
    Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.